• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by MiMedx Group Inc

    2/13/26 1:00:16 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    MiMedx Group, Inc.

    (Name of Issuer)


    Common Stock, Par Value of $0.001 Per Share

    (Title of Class of Securities)


    602496101

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    602496101


    1Names of Reporting Persons

    Trigran Investments, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ILLINOIS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,688,192.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,163,384.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,163,384.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    IA, CO

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    602496101


    1Names of Reporting Persons

    Douglas T. Granat
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,688,192.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,163,384.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,163,384.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    602496101


    1Names of Reporting Persons

    Lawrence A. Oberman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,688,192.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,163,384.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,163,384.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    602496101


    1Names of Reporting Persons

    Steven G. Simon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,688,192.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,163,384.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,163,384.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    602496101


    1Names of Reporting Persons

    Bradley F. Simon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,688,192.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,163,384.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,163,384.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    602496101


    1Names of Reporting Persons

    Steven R. Monieson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,688,192.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,163,384.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,163,384.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MiMedx Group, Inc.
    (b)Address of issuer's principal executive offices:

    1775 West Oak Commons Court NE Marietta, GA, 30062
    Item 2. 
    (a)Name of person filing:

    See Item 2(c)
    (b)Address or principal business office or, if none, residence:

    See Item 2(c)
    (c)Citizenship:

    Trigran Investments, Inc., 630 Dundee Road, Suite 230, Northbrook, IL 60062 (Illinois corporation) Douglas T. Granat, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Lawrence A. Oberman, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Steven G. Simon, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Bradley F. Simon, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Steven R. Monieson, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen)
    (d)Title of class of securities:

    Common Stock, Par Value of $0.001 Per Share
    (e)CUSIP No.:

    602496101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference to Item 9 of the cover page pertaining to each reporting person. Douglas Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon, and Steven R. Monieson are the controlling shareholders and officers of Trigran Investments, Inc. and thus may be considered the beneficial owners of shares beneficially owned by Trigran Investments, Inc.
    (b)Percent of class:

    Incorporated by reference to Item 11 of the cover page pertaining to each reporting person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Incorporated by reference to Item 5 of the cover page pertaining to each reporting person.

     (ii) Shared power to vote or to direct the vote:

    Incorporated by reference to Item 6 of the cover page pertaining to each reporting person.

     (iii) Sole power to dispose or to direct the disposition of:

    Incorporated by reference to Item 7 of the cover page pertaining to each reporting person.

     (iv) Shared power to dispose or to direct the disposition of:

    Incorporated by reference to Item 8 of the cover page pertaining to each reporting person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Trigran Investments, Inc.
     
    Signature:/s/ Lawrence A. Oberman
    Name/Title:Executive Vice President
    Date:02/13/2026
     
    Douglas T. Granat
     
    Signature:/s/ Douglas Granat
    Name/Title:Executive Officer of Trigran Investments, Inc.
    Date:02/13/2026
     
    Lawrence A. Oberman
     
    Signature:/s/ Lawrence A. Oberman
    Name/Title:Executive Vice President of Trigran Investments, Inc
    Date:02/13/2026
     
    Steven G. Simon
     
    Signature:/s/ Steve G. Simon
    Name/Title:Steve G. Simon
    Date:02/13/2026
     
    Bradley F. Simon
     
    Signature:/s/ Bradley F. Simon
    Name/Title:Bradley F. Simon
    Date:02/13/2026
     
    Steven R. Monieson
     
    Signature:/s/ Steven R. Monieson
    Name/Title:Steven R. Monieson
    Date:02/13/2026
    Exhibit Information

    Exhibit 1: Agreement to Make a Joint Filing

    Get the next $MDXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    5/5/25 10:06:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/22/23 5:01:18 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

    MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Summit Products Group ("Summit") to distribute three innovative, 510(k) cleared products that complement the Company's leading Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plus. About the products: Hydrelix Collagen Matrix is a sterile, Type 1 collagen powder, comprised of soluble modified bovine collagen. The product is formulated from hydrolyzed and modified collagens in powdered form, bypassing the need for further enzymatic degradation by the body. This allows the bioactive components of c

    2/4/26 10:27:02 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

    MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the 15th anniversary of EPIFIX and AMNIOFIX, the Company's placental allografts used in wound care and surgical recovery settings. "We are thrilled to mark the 15th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovation in the space," stated Randall Spencer, MIMEDX Vice President, Clinical Innovation. "Over the years, MIMEDX has changed the paradigm of wound care treatment and surgical recovery. The Company's products have become the placental allografts of choice across many specialti

    2/2/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

    MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company's Advanced Wound Care portfolio and is backed by multiple published studies eval

    12/22/25 9:43:46 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by MiMedx Group Inc

    SCHEDULE 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    2/13/26 1:00:16 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MiMedx Group Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    1/12/26 8:04:52 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    10/29/25 4:07:26 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Maersk-Moller Kimberly sold $432,329 worth of shares (58,300 units at $7.42), decreasing direct ownership by 20% to 236,982 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/10/25 5:14:43 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 6% to 188,024 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    7/7/25 5:59:59 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 12,034 shares, decreasing direct ownership by 4% to 295,282 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/26/25 4:48:44 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

    Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

    7/2/24 7:38:13 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on MiMedx Group with a new price target

    Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    3/7/24 8:26:30 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on MiMedx Group with a new price target

    Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    10/27/23 9:04:53 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Financials

    Live finance-specific insights

    View All

    MIMEDX Announces Record Revenue for Third Quarter 2025

    Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today, October 29, 2025, at 4:30 PM ET MARIETTA, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, comment

    10/29/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29

    MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13755619 A replay of the webcast will be available for approximately 30 days on the Company's

    10/15/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

    Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

    7/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

    MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

    6/26/24 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Appointment of Two New Independent Directors

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/12/24 4:04:33 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MiMedx Group Inc

    SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/4/24 1:30:50 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care